Keytruda met one of its primary endpoints in Phase III KEYNOTE 355 trial + chemotherapy for metastatic triple-negative breast cancer.- Merck Inc.
Related news and insights
CytoDyn Inc. a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced that Health Canada authorized the emergency use of leronlimab for the treatment of a patient with metastatic triple-negative breast cancer (mTNBC).
Gilead Sciences, Inc. reported that the Everest Medicines (HKEX 1952.HK) sponsored Phase IIb EVER-132-001 study of sacituzumab govitecan (marketed as Trodelvy in the United States) met its primary endpoint of overall response rate (ORR) in metastatic triple-negative breast cancer (TNBC).
Merck Inc announced that the European Commission (EC) has approved Keytruda (pembrolizumab), in combination with chemotherapy for the first-line treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) in adults whose tumors express PD-L1 (Combined Positive Score [CPS] of at least 10) and who have not received prior chemotherapy for metastatic disease.